Adrian Stecyk serves as Chief Executive Officer of Myrtelle. He is co-founder of Myrtelle and in March 2024 accepted the role of CEO.
Read BioJeff joined the company in 2021 and is involved with evaluating safety and efficacy of locally delivered therapeutics.
Read BioJenna joined the company in 2021, bringing more than 15 years of financial and operational leadership experience.
Read BioAlicia Fiscus serves as Regulatory Advisor, with over 20 years of industry experience including the operation of a successful regulatory and clinical development consulting practice.
Read BioOlga Flamini joined the company in 2021, serving as the Co-Chief Medical Officer, where she brings her expertise to the forefront of clinical development plans.
Read BioJordana joined the company in 2021, bringing more than 20 years of experience in leadership roles in the non-profit/rare disease sector.
Read BioStephanos joined the company in 2021, bringing more than 15 years of experience in various roles in biotech and Contract Testing Organizations.
Read BioNancy joined the company at its inception in 2021 and brings more than 25 years of experience in drug development.
Read BioRick joined the company in 2021, bringing more than 25 years of experience in the development of CNS therapies within the medical device, pharmaceutical, and gene therapy industries.
Read BioThomas joined the company in 2022 and brings nearly 15 years of experience to the Myrtelle Finance team.
Read BioDr. Joshua Merritt joined the company in 2024 bringing over 20 years of experience in biologics process development, manufacturing, and drug development.
Read BioDr. Michael Muhonen joined the company in 2024 and brings with him over 30 years of neurological, neurosurgical, and research expertise.
Read BioCassandra joined the company in the fall of 2021 and brings more than 15 years of administrative and facilities management experience.
Read Bio